# Mark Egly Foundation - Messaging Framework & Talking Points

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Communications Lead & Executive Director
**Purpose**: Ensure consistent, compelling messaging across all audiences and channels

---

## üìã Table of Contents

1. [Core Messaging Framework](#core-messaging-framework)
2. [Audience-Specific Messages](#audience-specific-messages)
3. [Elevator Pitches](#elevator-pitches)
4. [Key Statistics & Talking Points](#key-statistics--talking-points)
5. [Frequently Asked Questions](#frequently-asked-questions)
6. [Crisis Communication](#crisis-communication)
7. [Media Talking Points](#media-talking-points)

---

## Core Messaging Framework

### The Problem (In One Sentence)

**"AATD patients wait an average of 7-8 years and see 4+ doctors before being diagnosed‚Äîdelays that cause irreversible lung damage and preventable suffering."**

---

### The Solution (In One Sentence)

**"Mark Egly Foundation eliminates diagnostic delays through physician education, patient support, research innovation, and policy advocacy."**

---

### The Urgency (In One Sentence)

**"Every year of delay means progression of disease‚Äîwe must act now to save lives and lung function."**

---

### The Hope (In One Sentence)

**"By 2030, we will cut diagnostic delays in half, ensuring every AATD patient gets answers and treatment before it's too late."**

---

## Core Messages (Pillars)

### Pillar 1: The Crisis

**Message**: _AATD diagnostic delays are a preventable crisis causing suffering and preventable disease progression._

**Supporting Points**:

- 7-8 year average delay from first symptoms to diagnosis
- 4+ doctors consulted before correct diagnosis
- Estimated 100,000 diagnosed, but 300,000+ undiagnosed in the U.S.
- Delays lead to irreversible lung damage (emphysema) and liver disease
- Many patients misdiagnosed with asthma, COPD, or bronchitis for years

**Why It Matters**: We must communicate the stakes clearly‚Äîdiagnostic delays aren't just inconvenient, they're dangerous.

---

### Pillar 2: The Solution

**Message**: _Mark Egly Foundation tackles diagnostic delays through four proven strategies: Education, Support, Research, and Advocacy._

**Supporting Points**:

- **Education**: Training physicians to recognize AATD and test early
- **Support**: Helping patients navigate testing, treatment, and healthcare system
- **Research**: Funding innovations like quick-test devices and mass AAT production
- **Advocacy**: Pushing for policies like newborn screening and workplace protections

**Why It Matters**: We're not just raising awareness‚Äîwe're solving the problem systemically.

---

### Pillar 3: Mark's Story

**Message**: _Founded by Mark Egly, a PGA golf professional who self-diagnosed after 7 years of medical run-around, the foundation brings personal urgency and innovative thinking to AATD._

**Supporting Points**:

- Mark experienced the diagnostic delay crisis firsthand
- Self-diagnosed after doctors missed it repeatedly
- Holds patent (US20220160847) for repurposing AAT protein for firefighters, military, and asthma patients
- Turned personal frustration into mission to help others avoid same delays
- Brings business innovation mindset to rare disease space

**Why It Matters**: Mark's story is our origin story‚Äîit's authentic, relatable, and demonstrates why we're uniquely positioned to solve this.

---

### Pillar 4: Measurable Impact

**Message**: _We measure success not by awareness, but by reduced diagnostic delays and improved patient outcomes._

**Supporting Points**:

- Goal: Cut diagnostic delays in half (7-8 years ‚Üí 3-4 years) by 2030
- Track Diagnostic Delay Time (DDT) as our north star metric
- Transparent reporting: Quarterly updates on progress
- Evidence-based approach: Every program designed to move the needle on delays
- Real results: By Year 5, 10,000 patients served, 2,000 physicians trained, 5 states with newborn screening

**Why It Matters**: Donors and supporters want to know their contributions make a difference‚Äîwe prove it with data.

---

## Audience-Specific Messages

### For AATD Patients & Families

**Primary Message**: _You're not alone. We're here to help you get diagnosed, get treatment, and live your best life with AATD._

**Key Points**:

- We understand the frustration of not having answers
- Free patient navigation services to help you access testing and treatment
- Support groups and community (Alpha1Life.com)
- Financial assistance for testing and treatment costs
- Advocacy for your rights (insurance coverage, workplace protections)

**Tone**: Empathetic, supportive, practical

**Call-to-Action**: "Get Help Now" (link to patient services)

---

### For At-Risk Individuals (Undiagnosed)

**Primary Message**: _If you have unexplained breathing problems, chronic bronchitis, or family history of lung/liver disease, you might have AATD. Get tested._

**Key Points**:

- AATD is genetic and often undiagnosed (90%+ of people with AATD don't know)
- Simple blood test can diagnose
- Early detection allows for treatment and lifestyle changes to slow progression
- Testing is covered by most insurance (we can help if not)
- Family members should also get tested (genetic condition)

**Tone**: Informative, empowering, non-alarmist

**Call-to-Action**: "Get Tested" (link to testing resources)

---

### For Physicians & Healthcare Providers

**Primary Message**: _AATD is underdiagnosed because it's under-recognized. We provide free CME training to help you identify and diagnose AATD early._

**Key Points**:

- Average delay is 7-8 years because symptoms mimic common conditions (asthma, COPD)
- Early detection allows for augmentation therapy and prevents irreversible lung damage
- WHO recommends testing everyone with COPD‚Äîonly 10% of U.S. physicians do
- Our free, accredited CME course trains you to recognize AATD and order correct tests
- AATD Aware certification seal for your practice (like Fair Underwriting)
- Malpractice risk: Missing AATD diagnosis can lead to liability

**Tone**: Professional, evidence-based, respectful

**Call-to-Action**: "Take Free CME Course" (link to medical education program)

---

### For Donors & Funders

**Primary Message**: _Your investment in Mark Egly Foundation directly reduces diagnostic delays, saving lives and preventing suffering._

**Key Points**:

- Every dollar goes toward measurable impact (80% to programs, not overhead)
- Transparent reporting: See exactly how your gift makes a difference
- Innovative approach: We're not just raising awareness, we're changing systems
- Leverage: Your gift is multiplied (e.g., CME course trains 1,000 physicians who each diagnose 10 patients = 10,000 lives changed)
- Proven leadership: Founded by AATD patient who holds patent and brings business innovation to rare disease

**Tone**: Inspiring, urgent, data-driven

**Call-to-Action**: "Donate Now" (link to donation page)

---

### For Policymakers & Legislators

**Primary Message**: _Policy change is essential to ending AATD diagnostic delays. We advocate for newborn screening, workplace protections, and insurance coverage._

**Key Points**:

- State-level newborn screening for AATD reduces delays by 90%
- Firefighters and military face higher AATD risk due to smoke/dust exposure
- Current policies leave AATD patients vulnerable to discrimination and lack of coverage
- Model legislation available (we make your job easy)
- Bipartisan issue: Early detection saves healthcare costs and improves outcomes
- Constituent voices: Real AATD patients in your district need your leadership

**Tone**: Assertive, data-driven, solution-oriented

**Call-to-Action**: "Cosponsor Legislation" or "Meet with Constituent" (specific ask)

---

### For Media & Journalists

**Primary Message**: _AATD is a hidden epidemic affecting 300,000+ Americans who don't know they have it‚Äîand diagnostic delays are causing preventable suffering._

**Key Points**:

- Human interest angle: Mark's story (PGA golfer who self-diagnosed)
- Data/investigative angle: Why are patients waiting 7-8 years for diagnosis?
- Policy angle: States without newborn screening vs. states with it
- Innovation angle: Mark's patent for repurposing AAT protein
- Local angle: How many AATD patients in your coverage area? What resources exist?

**Tone**: Newsworthy, credible, story-driven

**Call-to-Action**: "Interview Mark Egly" or "Feature Patient Story" (media kit available)

---

### For Corporate Partners

**Primary Message**: _Partnering with Mark Egly Foundation aligns your company with life-saving innovation and demonstrates commitment to rare disease community._

**Key Points**:

- Employee engagement opportunities (volunteer programs, workplace giving)
- Cause marketing campaigns (portion of sales supports AATD awareness)
- Research partnerships (pharmaceutical, genetic testing, device companies)
- Visibility: Logo on website, materials, events
- Impact: Your partnership funds X tests, X CME courses, X advocacy campaigns
- Tax benefits: 501(c)(3) charitable contributions

**Tone**: Professional, mutually beneficial, impact-focused

**Call-to-Action**: "Explore Partnership Opportunities" (contact development team)

---

## Elevator Pitches

### 30-Second Pitch (Networking, Casual Conversations)

_"I work with the Mark Egly Foundation. We're a nonprofit working to eliminate diagnostic delays for AATD‚Äîa genetic lung disease that affects 300,000 Americans but takes an average of 7-8 years to diagnose. Every year of delay means more lung damage, so we're training doctors, supporting patients, and pushing for policy changes to cut those delays in half by 2030. It's named after Mark Egly, a PGA golfer who went through the diagnostic nightmare himself and decided to fix the system."_

---

### 60-Second Pitch (Donor Meetings, Introductions)

_"The Mark Egly Foundation eliminates diagnostic delays for Alpha-1 Antitrypsin Deficiency, or AATD‚Äîa genetic condition that causes lung and liver disease. Here's the crisis: An estimated 300,000 Americans have AATD but don't know it, and those who do know waited an average of 7-8 years to get diagnosed. By the time they're diagnosed, many have irreversible lung damage._

_We're solving this through four strategies: First, educating physicians with free CME courses so they recognize AATD earlier. Second, supporting patients with navigation services and financial assistance. Third, funding research like quick-test devices and new treatments. And fourth, advocating for policies like newborn screening._

_Our founder, Mark Egly, is a PGA golfer who experienced this diagnostic delay firsthand and even holds a patent for repurposing the AATD protein for firefighters and military. Our goal is ambitious but achievable: Cut diagnostic delays in half by 2030. That means thousands of people will get diagnosed before it's too late."_

---

### 2-Minute Pitch (Formal Presentations, Major Donor Cultivation)

_"Imagine experiencing shortness of breath, chronic coughing, and constant fatigue‚Äîbut every doctor you see tells you it's just asthma or bronchitis. You try inhaler after inhaler, but nothing works. Seven years go by. Four different doctors. Finally, one orders the right blood test, and you learn you have Alpha-1 Antitrypsin Deficiency‚Äîa genetic condition that's been destroying your lungs this entire time. Now the damage is irreversible._

_This is the reality for 100,000 diagnosed AATD patients in the U.S. And it's the reality that an estimated 300,000 more will face if we don't change the system. That's why the Mark Egly Foundation exists._

_We were founded by Mark Egly, a PGA golf professional who lived this nightmare himself. After years of being misdiagnosed, Mark finally figured it out on his own. But instead of just moving on, he decided to fix the broken system. He's even patented an innovation for repurposing the AAT protein to help firefighters, military personnel, and asthma patients._

_Our strategy is comprehensive: We're training physicians through free, accredited CME courses so they recognize AATD early. We're supporting patients with navigation services, financial assistance, and community‚Äîbecause diagnosis is just the first step. We're funding research into innovations like quick-circulating AAT test devices and mass protein production. And we're advocating for policy changes like newborn screening and workplace protections for high-risk groups._

_But here's what sets us apart: We don't just measure awareness. We measure impact. Our north star metric is Diagnostic Delay Time‚Äîthe time from first symptoms to diagnosis. And we've set a bold, measurable goal: Cut that 7-8 year average in half by 2030._

_By Year 5, we'll have trained 2,000 physicians, served 10,000 patients, and helped pass newborn screening laws in 5 states. That's not just awareness‚Äîthat's lives saved and suffering prevented._

_And we're transparent about it. Every quarter, we report on our progress publicly. Donors and supporters can see exactly how their contributions move the needle._

_This is personal for us. It's urgent. And it's solvable. With your support, we're going to eliminate AATD diagnostic delays and ensure that no one else has to wait 7 years for answers. Thank you."_

---

## Key Statistics & Talking Points

### AATD Overview

‚úÖ **"Alpha-1 Antitrypsin Deficiency (AATD) is a genetic condition that causes lung disease (emphysema) and liver disease."**

‚úÖ **"An estimated 100,000 people in the U.S. are diagnosed with AATD, but 300,000+ more have it and don't know."**

‚úÖ **"AATD is caused by mutations in the SERPINA1 gene and is inherited from both parents."**

‚úÖ **"Severe AATD (ZZ genotype) leads to emphysema in 30s-50s, much earlier than typical COPD."**

‚úÖ **"The only specific treatment is augmentation therapy‚Äîweekly infusions of AAT protein to slow disease progression."**

---

### Diagnostic Delays

‚úÖ **"The average time from first symptoms to AATD diagnosis is 7-8 years."**

‚úÖ **"Patients see an average of 4+ doctors before being correctly diagnosed."**

‚úÖ **"Diagnostic delays lead to irreversible lung damage and preventable disease progression."**

‚úÖ **"Many AATD patients are initially misdiagnosed with asthma, COPD, or bronchitis."**

‚úÖ **"Early detection allows for treatment (augmentation therapy) and lifestyle changes that slow progression."**

---

### Why Delays Happen

‚úÖ **"AATD is under-recognized by physicians because it's rare and symptoms mimic common conditions."**

‚úÖ **"The World Health Organization recommends testing all COPD patients for AATD, but only 10% of U.S. physicians do."**

‚úÖ **"Medical schools spend little time on AATD‚Äîmany doctors graduate without learning about it."**

‚úÖ **"A simple blood test can diagnose AATD, but doctors have to think to order it."**

---

### Mark Egly Foundation Impact (Goals)

‚úÖ **"Our goal is to cut diagnostic delays in half‚Äîfrom 7-8 years to 3-4 years‚Äîby 2030."**

‚úÖ **"By Year 5, we'll train 2,000 physicians, serve 10,000 patients, and help pass newborn screening laws in 5 states."**

‚úÖ **"We allocate 80%+ of our budget directly to programs‚Äîeducation, support, research, and advocacy."**

‚úÖ **"Every dollar donated funds tangible impact: $50 = 1 AATD test, $500 = 1 month of patient navigation, $5,000 = 50 physicians trained."**

---

### Mark's Story

‚úÖ **"Mark Egly is a PGA golf professional who experienced 7 years of diagnostic delays before figuring out he had AATD."**

‚úÖ **"After being misdiagnosed repeatedly, Mark researched his symptoms and self-diagnosed, then confirmed with a blood test."**

‚úÖ **"Mark holds a patent (US20220160847) for repurposing AAT protein to help firefighters, military personnel, and asthma patients."**

‚úÖ **"Mark founded the foundation to ensure no one else has to go through what he went through."**

---

### Policy & Advocacy

‚úÖ **"Newborn screening for AATD reduces diagnostic delays by 90%‚Äîbabies are identified at birth and monitored throughout life."**

‚úÖ **"Only a handful of U.S. states include AATD in newborn screening panels‚Äîwe're advocating for nationwide adoption."**

‚úÖ **"Firefighters and military personnel face higher AATD risk due to smoke and dust exposure, but lack workplace protections."**

‚úÖ **"Insurance coverage for AATD testing and treatment is inconsistent‚Äîwe're fighting for comprehensive coverage."**

---

## Frequently Asked Questions (FAQs)

### General AATD Questions

**Q: What is AATD?**
A: Alpha-1 Antitrypsin Deficiency (AATD) is a genetic condition that causes low levels of the AAT protein, which protects the lungs and liver. Low AAT leads to lung disease (emphysema) and liver disease. It's inherited from both parents and affects an estimated 300,000+ Americans.

**Q: What are the symptoms of AATD?**
A: Common symptoms include shortness of breath, wheezing, chronic cough, frequent respiratory infections, and fatigue. Symptoms often mimic asthma or COPD, which is why AATD is frequently misdiagnosed. Some people also develop liver disease (cirrhosis).

**Q: How is AATD diagnosed?**
A: A simple blood test measures AAT protein levels and identifies genetic mutations. If levels are low, genetic testing confirms the specific SERPINA1 gene mutations (e.g., ZZ, SZ, MZ).

**Q: Is there a cure for AATD?**
A: There's no cure, but augmentation therapy (weekly infusions of AAT protein) can slow lung disease progression. Liver transplant is the only cure for severe liver disease. Early detection and lifestyle changes (avoiding smoking, reducing lung irritants) also help.

**Q: Who should get tested for AATD?**
A: The WHO recommends testing everyone with COPD. You should also get tested if you have unexplained lung disease, family history of AATD, chronic liver disease, or certain occupational exposures (firefighters, military).

---

### Mark Egly Foundation Questions

**Q: What does Mark Egly Foundation do?**
A: We eliminate AATD diagnostic delays through four strategies: (1) educating physicians with free CME courses, (2) supporting patients with navigation and financial assistance, (3) funding research innovations like quick-test devices, and (4) advocating for policies like newborn screening.

**Q: How is this foundation different from Alpha-1 Foundation?**
A: Alpha-1 Foundation (established nonprofit) focuses primarily on research funding and patient resources. Mark Egly Foundation focuses specifically on eliminating diagnostic delays through physician education, policy advocacy, and innovation. We complement each other and collaborate when appropriate.

**Q: Is Mark Egly Foundation a 501(c)(3)?**
A: Yes, we're a registered 501(c)(3) nonprofit. Donations are tax-deductible to the fullest extent of the law. Our EIN is [TBD].

**Q: How much of my donation goes to programs vs. overhead?**
A: 80%+ of our budget goes directly to programs (education, support, research, advocacy). Less than 15% goes to administration and less than 5% to fundraising costs. We're committed to transparency and publish financial reports quarterly.

**Q: Can I donate in honor of someone with AATD?**
A: Absolutely. You can make a tribute gift in honor or memory of a loved one, and we'll send them (or their family) a notification. Visit our donation page for details.

---

### Getting Help Questions

**Q: I think I might have AATD. What should I do?**
A: Contact our patient navigation team at [email/phone]. We'll help you access testing (often covered by insurance or available at low/no cost), interpret results, connect with specialists, and access treatment.

**Q: I'm an AATD patient struggling with medical costs. Can you help?**
A: Yes. Our patient assistance program helps with testing costs, treatment co-pays, travel to specialists, and oxygen equipment. Contact us at [email/phone] to apply.

**Q: Is there a support group for AATD patients?**
A: Yes! We facilitate support groups (virtual and in-person) and host the Alpha1Life.com online community where you can connect with other patients and families.

---

## Crisis Communication

### When to Use Crisis Communication Protocols

**Situations**:

- Data breach or privacy violation
- Negative media coverage or controversy
- Major donor or partner dispute
- Allegation of misconduct (staff, board, volunteer)
- Financial irregularity or audit issue
- Patient harm or safety issue

---

### Crisis Response Framework

**1. Assess & Contain** (within 1 hour):

- What happened? What are the facts?
- Who is affected?
- Is there immediate danger? If so, address first.
- Pause external communications until facts are clear.

**2. Assemble Crisis Team** (within 2 hours):

- Executive Director, Board Chair, Communications Lead
- Legal counsel (if needed)
- Relevant staff

**3. Craft Holding Statement** (within 4 hours):

- Acknowledge the situation
- Express concern and commitment to addressing
- Share what we know so far (stick to facts)
- Outline next steps
- Provide contact for questions

**Example Holding Statement**:
_"Mark Egly Foundation is aware of [situation]. We take this matter very seriously and are conducting a thorough review. The safety and privacy of our patients and community is our top priority. We will share more information as it becomes available. For questions, please contact [name] at [email/phone]."_

**4. Investigate & Respond** (within 24-48 hours):

- Gather all facts
- Consult legal/HR as needed
- Determine appropriate response
- Draft detailed statement
- Identify spokesperson (usually Executive Director or Board Chair)

**5. Communicate Transparently**:

- Share what happened and why
- Take responsibility (if appropriate)
- Outline corrective actions
- Commit to preventing future issues

**6. Monitor & Follow Up**:

- Monitor media and social media
- Respond to questions consistently
- Provide updates as situation evolves
- Conduct post-crisis debrief to improve protocols

---

### Crisis Talking Points Template

**Acknowledge**:
_"We're aware of [issue] and take it very seriously."_

**Express Concern**:
_"Our top priority is [patient safety / data security / transparency / etc.]."_

**Share Facts**:
_"Here's what we know so far: [brief, factual summary]."_

**Outline Response**:
_"We're [investigating / addressing / correcting] by [specific actions]."_

**Commit to Improvement**:
_"We're committed to learning from this and ensuring it doesn't happen again."_

**Provide Contact**:
_"For questions, please contact [name] at [email/phone]."_

---

### What NOT to Say in a Crisis

‚ùå "No comment." (Sounds evasive)
‚ùå "It's not a big deal." (Minimizes concern)
‚ùå "That's not true." (Without evidence to back it up)
‚ùå "We can't talk about it." (Without explanation)
‚ùå "It's not our fault." (Defensive)

**Instead**: Be honest, empathetic, and solution-focused.

---

## Media Talking Points

### For Media Interviews (General)

**Do**:

- ‚úÖ Prepare 3 key messages in advance
- ‚úÖ Stick to your expertise (AATD and foundation programs)
- ‚úÖ Use plain language (avoid jargon)
- ‚úÖ Tell patient stories (with permission)
- ‚úÖ Cite credible sources (WHO, research studies)
- ‚úÖ Bridge back to key messages ("What's important to understand is...")
- ‚úÖ Be authentic and passionate

**Don't**:

- ‚ùå Speculate or guess
- ‚ùå Say "no comment" (offer to follow up instead)
- ‚ùå Go off the record (assume everything is on the record)
- ‚ùå Badmouth other organizations
- ‚ùå Make promises you can't keep

---

### Media Interview Template

**Reporter**: _Tell me about Mark Egly Foundation._

**You**: _Mark Egly Foundation eliminates diagnostic delays for AATD, a genetic lung disease that affects 300,000 Americans but takes 7-8 years to diagnose. We train doctors, support patients, fund research, and advocate for policy changes. Our goal is to cut diagnostic delays in half by 2030._

---

**Reporter**: _What's the impact of diagnostic delays?_

**You**: _Every year of delay means progression of irreversible lung disease. By the time many AATD patients are diagnosed, they've already lost significant lung function. Early detection allows for treatment‚Äîaugmentation therapy‚Äîthat can slow progression and improve quality of life. That's why our work is so urgent._

---

**Reporter**: _Why does it take so long to diagnose AATD?_

**You**: _AATD symptoms mimic common conditions like asthma and COPD, so doctors often don't think to test for it. Medical schools spend little time on rare diseases, so many physicians aren't familiar with AATD. The World Health Organization recommends testing all COPD patients for AATD, but only 10% of U.S. doctors actually do. We're changing that through education and advocacy._

---

**Reporter**: _Tell me about Mark Egly._

**You**: _Mark is a PGA golf professional who went through the diagnostic delay crisis himself‚Äî7 years of seeing doctors who missed his AATD. He finally self-diagnosed and confirmed it with a blood test. But instead of just moving on, he founded this organization to fix the system. He even holds a patent for repurposing the AAT protein to help firefighters and military personnel. His story is our "why"‚Äîit's personal, urgent, and drives everything we do._

---

**Reporter**: _What can people do to help?_

**You**: _Three things: First, if you have unexplained breathing problems or family history of lung disease, get tested for AATD. Second, spread the word‚Äîmany people have never heard of AATD. And third, support our work. Donate at MarkEglyFoundation.org or volunteer. Every contribution helps us reach more doctors, help more patients, and ultimately save lives._

---

## Summary: Consistency is Key

**Why Messaging Matters**:

- Consistent messages build recognition and trust
- Clear talking points ensure we're "on brand" across all spokespeople
- Prepared responses prevent miscommunication in high-stakes situations

**Who Should Use This Document**:

- Mark Egly (founder)
- Executive Director
- Board members
- Staff
- Volunteers (especially ambassadors and advocates)
- Anyone representing Mark Egly Foundation publicly

**When to Use**:

- Media interviews
- Donor meetings
- Networking events
- Presentations
- Social media posts
- Website copy
- Grant applications
- Advocacy meetings

**Remember**: You don't have to memorize every word, but **know the core messages** and **speak from the heart** with data to back it up.

---

**Approved by**: Mark Egly Foundation Board of Directors
**Effective Date**: November 7, 2025
**Review Date**: Annually (or as needed for major updates)
**Version**: 1.0

---

_"Our message is our mission‚Äîtold clearly, consistently, and with urgency."_

**‚Äî Mark Egly Foundation Communications Team**
